ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

This award recognizes Dr. Nkrumah-Elie’s dedication to advancing scientific excellence for ChromaDex’s leading external research program and mentorship in the dietary supplement industry

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that Radicle Science and Council for Responsible Nutrition (CRN) honored Yasmeen Nkrumah-Elie, Ph.D, ChromaDex’s Global Director of External Research, as the winner of the inaugural Trailblazing Woman Award.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015810330/en/

Yasmeen Nkrumah-Elie, Ph.D accepts the Trailblazing Woman Award on stage during CRN’s CONVERGENCE Conference (Photo: Business Wire)

Yasmeen Nkrumah-Elie, Ph.D accepts the Trailblazing Woman Award on stage during CRN’s CONVERGENCE Conference (Photo: Business Wire)

“I am deeply honored to receive the Trailblazing Woman Award,” said Dr. Nkrumah-Elie, “and I am moved by the collective force of inspiring women leading within our dietary supplement industry who continue to push the boundaries of what’s possible—as my fellow finalists demonstrate. I am grateful for the opportunity to be a part of an industry dedicated to advancing wellness and improving global health.”

The Trailblazing Woman Award honors women who have made remarkable contributions to the dietary supplement and functional food industry through leadership, innovation, and mentorship. Dr. Nkrumah-Elie was selected for her extraordinary commitment to advancing science, promoting diversity, and mentoring the next generation of female leaders.

In addition to her leadership role at ChromaDex, Dr. Nkrumah-Elie is a member of CRN’s Senior Scientific Advisory Council and actively contributes to several industry organizations, including Women In Nutraceuticals (WIN) and the American Society for Nutrition, where she advocates for diversity, equity, and inclusion. She is a frequent speaker at industry conferences, where she shares her knowledge and helps bridge the gap between science and broader audiences.

Andrew Shao, PhD., Senior Vice President, Global Scientific and Regulatory Affairs, ChromaDex, commented: “Dr. Nkrumah-Elie has led the evolution of the ChromaDex External Research Program (CERP) to become an award-winning and industry-leading research program. Under her leadership, CERP has amassed nearly 300 research collaborations with institutions around the world, over 30 published clinical trials and several intellectual property opportunities. Dr. Nkrumah-Elie and her dedicated team have elevated CERP to become the gold standard for industry-academia collaboration.”

“We’re thrilled to celebrate Dr. Nkrumah-Elie’s remarkable achievements and the lasting impact she’s made on our industry,” said Pelin Thorogood, Co-Founder and Executive Chairwoman of Radicle Science. “A brilliant researcher, Dr. Nkrumah-Elie’s influence extends far beyond her scientific contributions—she’s a mentor, a connector, and a fierce advocate for women in science. Her passion for creating opportunities and uniting people in meaningful ways is why she’s such a worthy recipient of our inaugural Trailblazing Woman Award.”

“We appreciate Dr. Nkrumah-Elie’s engagement and leadership in the CRN member community,” said Andrea Wong, Ph.D., CRN Senior Vice President, Scientific and Regulatory Affairs. “Her depth of knowledge, combined with her dedication to advancing scientific excellence and mentoring future generations, has made a significant impact.”

About ChromaDex:

ChromaDex Corp. (NASDAQ: CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription (www.niagenplus.com).

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.

Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.